Workboat Indexes

Zevra Therapeutics, Inc. - Common Stock (NQ: ZVRA )

8.180 +1.880 (+29.84%)

Streaming Delayed Price Updated: 1:08 PM EDT, Aug 5, 2024 Add to My Watchlist

Price and Volume

Volume	7,074,156
Open	7.500
Bid (Size)	8.170 (9)
Ask (Size)	8.180 (2)
Prev. Close	6.300
Today's Range	7.350 - 8.440
52wk Range	3.890 - 7.280
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Today 8:54 EDT

Via Benzinga

FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases

Today 7:59 EDT

FDA panel supports Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C with an 11-5 vote. William Blair boosts success probability to 90%, highlighting Zevra's growth and balanced rare...

Via Benzinga

Performance

YTD	+19.77%	+19.77%
1 Month	+92.02%	+92.02%
3 Month	+58.68%	+58.68%
6 Month	+41.77%	+41.77%
1 Year	+68.31%	+68.31%

More News

10 Health Care Stocks Whale Activity In Today's Session

July 23, 2024

Via Benzinga

Insiders Buying Zevra Therapeutics And 1 Other Stock

July 18, 2024

Via Benzinga

Zevra Therapeutics: Q4 Earnings Insights

March 28, 2024

Via Benzinga

Earnings Outlook For Zevra Therapeutics

March 27, 2024

Via Benzinga

Zevra Therapeutics's Earnings: A Preview

November 06, 2023

Via Benzinga

Insiders Buying Barnes & Noble Education And 2 Other Stocks

July 17, 2024

Via Benzinga

SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL

July 11, 2024

Via AB Newswire

FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base

July 09, 2024

Via Benzinga

ZVRA Stock Earnings: Zevra Therapeutics Beats EPS, Misses Revenue for Q1 2024

May 08, 2024

Via InvestorPlace

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) Letter to Stakeholders Looks Like Launch Code to Drive Value

May 06, 2024

Via Investor Brand Network

ZEVRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Zevra Therapeutics, Inc. on Behalf of Zevra Stockholders and Encourages Investors to Contact the Firm

April 03, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Zevra Therapeutics, Inc. (ZVRA)

April 02, 2024

From Kirby McInerney LLP

Via GlobeNewswire

ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q4 2023

March 28, 2024

Via InvestorPlace

Earnings Scheduled For March 28, 2024

March 28, 2024

Via Benzinga

Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday

December 28, 2023

Via Benzinga

BioMedNewsBreaks – Zevra Therapeutics Inc. (NASDAQ: ZVRA) Resubmits Arimoclomol New Drug Application to the FDA

December 27, 2023

Via Investor Brand Network

InvestorNewsBreaks — Zevra Therapeutics Inc. (NASDAQ: ZVRA) Names New President, CEO and Director

October 10, 2023

Via Investor Brand Network

Health Care Company Zevra Therapeutics Announces Merger With Acer Therapeutics

August 31, 2023

Via Benzinga

Why Is Acer Therapeutics Stock Trading Higher Today?

August 31, 2023

Via Benzinga

Earnings Scheduled For November 7, 2023

November 07, 2023

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq -

August 31, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Why Is Acer Therapeutics (ACER) Stock Up 85% Today?

August 31, 2023

Via InvestorPlace

Earnings Scheduled For August 14, 2023

August 14, 2023

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.